SCHEMBL25935487

SCHEMBL25935487

COC(=O)c1ccc(NCCC(=O)O)c(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 3/20 0.60
MAPT P10636 2/20 0.50
TDP1 Q9NUW8 1/20 0.50
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 3/20 0.49
HSD17B10 Q99714 2/20 0.49
HPGD P15428 1/20 0.49
GAA P10253 2/20 0.48
KMT2A Q03164 1/20 0.46
PYGL P06737 1/20 0.44
MGLL Q99685 1/20 0.44
APEX1 P27695 1/20 0.43
HIF1A Q16665 1/20 0.43
MAPK1 P28482 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
CA12 O43570 2/20 0.41
CA1 P00915 2/20 0.41
CA2 P00918 2/20 0.41
CA7 P43166 2/20 0.41
CA9 Q16790 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25031090 0.89 POLB (0.60) POLBMAPTTDP1ALDH1A1KDM4E
SCHEMBL9953947 0.84 HTT (0.55) POLBMAPTTDP1ALDH1A1KDM4E
SCHEMBL3210169 0.82 TDP1 (0.68) MAPTTDP1ALDH1A1KDM4EHPGD
SCHEMBL31161183 0.81 POLB (0.61) POLBMAPTTDP1ALDH1A1KDM4E
SCHEMBL25033933 0.81 APEX1 (0.62) POLBMAPTTDP1ALDH1A1KDM4E
SCHEMBL24670733 0.80 POLB (0.64) POLBMAPTTDP1ALDH1A1KDM4E
SCHEMBL23121876 0.80 TDP1 (0.68) POLBMAPTTDP1ALDH1A1KDM4E
SCHEMBL29720831 0.80 TDP1 (0.68) POLBMAPTTDP1ALDH1A1KDM4E
SCHEMBL21408921 0.78 HDAC1 (0.54) POLBMAPTTDP1GAAMAPK1
SCHEMBL29811877 0.78 MAPT (0.51) POLBMAPTALDH1A1KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116261458-B PLK1 degradation inducing compounds 厄普特拉株式会社 2024-05-24 CN disclosed
US-11939334-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers UPPTHERA, INC. (KR) 2024-03-26 US disclosed
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-08-03 US disclosed
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND UPPTHERA, INC. (KR) 2023-08-03 US disclosed
CN-116261458-A Novel PLK1 degradation inducing compounds 厄普特拉株式会社 2023-06-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11939334-B2 Substituted pyrimido[4,5-b][1,4]diazepines as PLK1 degradation inducers PLK1, BUB1B, BUB1 POLB 176/4885MAPT 1700/4885TDP1 414/4885
US-20230242541-A1 NOVEL PLK1 DEGRADATION INDUCING COMPOUND PLK1, BUB1B, BUB1 POLB 874/4885MAPT 2055/4885TDP1 880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.